[go: up one dir, main page]

KR900701295A - 양극성 펩타이드류와 그것에 관한 용도 - Google Patents

양극성 펩타이드류와 그것에 관한 용도

Info

Publication number
KR900701295A
KR900701295A KR1019900700089A KR900700089A KR900701295A KR 900701295 A KR900701295 A KR 900701295A KR 1019900700089 A KR1019900700089 A KR 1019900700089A KR 900700089 A KR900700089 A KR 900700089A KR 900701295 A KR900701295 A KR 900701295A
Authority
KR
South Korea
Prior art keywords
peptide
amino acids
amino acid
groups
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019900700089A
Other languages
English (en)
Inventor
미카엘 자스로프.
Original Assignee
원본미기재
마게이닌 사이언시스 인코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 마게이닌 사이언시스 인코포레이션 filed Critical 원본미기재
Publication of KR900701295A publication Critical patent/KR900701295A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

양극성 펩타이드류와 그것에 관한 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (24)

  1. A와 B는 친수성 아미노산으로 각각이 같거나 혹은 다른 아미노산일 수 있으며, C와 D중 하나는 염기성 친수성 아미노산이고 다른 하나는 양전하 또는 중성전하의 친수성 아미노산인 A-B그룹이 소수성 아미노산이 아닌 적어도 한 아미노산에 의해 나누어지는 적어도 A-B두 아미노산 그룹과 친수성 아미노산이 아닌 적어도 한 아미노산에 의해 분리되는 적어도 C-D두 아미노산그룹을 포함하는 최소 8개의 아미노산으로 이루언진 펩타이드.
  2. 제1항에 있어서, 8개에서 15개의아미노산을 가지고 있는 펩타이드.
  3. 제2항에 있어서, 다음의 배열중 하나를 포함하고 있는 펩타이드,
    n은 2나 3, a는 0 혹은 1 그리고 b는 0 혹은 1이다.
  4. 제1항에 있어서, A-B 네그룹의 아미노산과 최소 C-D 세그룹의 아미노산의 적어도 16개의 아미노산을 포함하는 펩타이드.
  5. 제1항에 있어서, 적어도 C-D 네 그룹의 아미노산이 있는 펩타이드.
  6. 제1항에 있어서, -A-B-C-D, -B-C-D-A, -C-D-A-B, -D-A-B-C- 적어도 네 그룹의 펩타이드 배열을 포함하는 펩타이드.
  7. 제6항에 있어서, 다음과 같은 배열중 하나를 포함하는 펩타이드,
  8. 제5항에 있어서, 알라닌(Ala), 페닐알라닌(Phe), 글리신(Gly), 이소루신(Ile), 루신(Leu), 메티오닌(Met), 발린(Val)과 트립토판(Trp)으로 구성되는 부류에서 선택된 소수성 아미노산, 세린(Ser), 트레오닌(Thr)으로 구성된 부류에서 선택된 중성전하의 친수성 아미노산과 리신(Lys), 아르기닌(Arg), 히스티딘(His)으로 구성된 부류에서 선택된 염기성 친수성 아미노산들로 이루어진 폴리 펩타이드.
  9. 제8항에 있어서, A와 B가 소수성 아미노산이고, C나 D중 하나는 중성 전하나 양성 전하의 친수성 아미노산이며 다른 하나는 염기성 친수성 아미노산인 배열 A-B-C-D롤 네 아미노산으로된 네그룹의 하나로 갖는 폴리 펩타이드.
  10. 제5항에 있어서, 다음의 배열을 포함하는 폴리 펩타이드. -(Ala-Phe-Ser-Lys)-
  11. 제6항에 있어서, 최소 20아미노산과 50아미노산 보다 크지 않은 아미노산 사슬로 되어 있는 폴리 펩타이드.
  12. 제6항에 있어서, 상기 배열의 다섯 그룹을 포함하는 폴리 펩타이드.
  13. 제6항에 있어서, 상기 배열의 여섯 그룹을 포함하는 폴리 펩타이드.
  14. 제1항에 있어서, 상기 네 아미노산의 중복 그룹을 포함하는 폴리 펩타이드.
  15. 제5항의 펩타이드를 효과적인 항미생물량 만큼 동물에게 투여하는 방법.
  16. 제5항의 펩타이드를 효과적인 항비루스양 만큼 동물에게 투여하는 방법.
  17. 제5항의 펩타이드를 효과적인 한 종기량 만큼 동물에게 투여하는 방법.
  18. 제5항의 펩타이드를 효과적인 항생제양 만큼 동물에게 투여하는 방법.
  19. 제5항의 펩타이드를 효과적인 항 살생자제양 만큼 동물에게 투여하는 방법.
  20. 제5항의 펩타이드의 효과적인 항미생물 양을 함유하는 조제 매개체로 구성된 조성물.
  21. 제5항의 펩타이드의 효과적인 항비루스 양을 함유하는 조제 매개체로 구성된 조성물.
  22. 제5항의 펩타이드의 효과적인 항생제 양을 함유히는 조제 매개체로 구성된 조성물.
  23. 제5항의 펩타이드의 효과적인 항종기 양을 함유하는 조제 매개체로 구성된 조성물.
  24. 제5항의 펩타이드의 효과적인 항살정자제 양을 함유하는 조제 매개체로 구성된 조성물.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019900700089A 1988-05-27 1989-05-19 양극성 펩타이드류와 그것에 관한 용도 Withdrawn KR900701295A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19992788A 1988-05-27 1988-05-27
US199,927 1988-05-27
PCT/US1989/002217 WO1989011290A1 (en) 1988-05-27 1989-05-19 Amphiphilic peptides and use thereof

Publications (1)

Publication Number Publication Date
KR900701295A true KR900701295A (ko) 1990-12-01

Family

ID=22739596

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700089A Withdrawn KR900701295A (ko) 1988-05-27 1989-05-19 양극성 펩타이드류와 그것에 관한 용도

Country Status (14)

Country Link
EP (1) EP0416035B1 (ko)
JP (1) JPH03504501A (ko)
KR (1) KR900701295A (ko)
CN (1) CN1040033A (ko)
AT (1) ATE115146T1 (ko)
AU (1) AU626890B2 (ko)
BR (1) BR8907452A (ko)
DE (1) DE68919848T2 (ko)
DK (1) DK280190A (ko)
ES (1) ES2012004A6 (ko)
FI (1) FI905825A0 (ko)
IL (1) IL90356A0 (ko)
PT (1) PT90642A (ko)
WO (1) WO1989011290A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792831A (en) * 1990-02-08 1998-08-11 Magainin Pharmaceuticals Inc. Analogues of magainin peptides containing D-amino acids
US5221664A (en) * 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
US5208220A (en) * 1990-06-27 1993-05-04 Magainin Pharmaceuticals, Inc. Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase
EP0472987B1 (en) * 1990-08-10 2005-11-02 Virtual Drug Development, Inc. Antimicrobial peptides active against plant pathogens, their use and screening methods pertaining thereto
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
US6348445B1 (en) 1992-06-01 2002-02-19 Magainin Pharmaceuticals, Inc. Biologically active peptides with reduced toxicity in animals and a method for preparing same
US5654274A (en) * 1992-06-01 1997-08-05 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
ES2316154T3 (es) * 1995-08-23 2009-04-01 University Of British Columbia Peptidos cationicos antimicrobianos y procedimientos de seleccion de los mismos.
CN107614004B (zh) * 2015-03-23 2022-12-06 激流生物科学有限公司 抗微生物肽及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE436645C (sv) * 1976-04-29 1996-07-22 Bonnierfoeretagen Ab Antigeniskt aktiv polypeptid, som kan användas vid cancerdiagnosticering och vid framställning av antikroppar
US4659692A (en) * 1982-11-19 1987-04-21 The Regents Of The University Of California Cationic oligopeptides having microbicidal activity
DE3324534A1 (de) * 1983-07-07 1985-01-17 Ciba-Geigy Ag, Basel Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel
US4617149A (en) * 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
DE3438296A1 (de) * 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
DE3689525D1 (de) * 1985-07-17 1994-02-24 Hoechst Ag Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel.
ATE106896T1 (de) * 1987-03-04 1994-06-15 Us Health Neue synthetische bioaktive verbindungen und verfahren zur herstellung bioaktiver wirkungen.

Also Published As

Publication number Publication date
DK280190D0 (da) 1990-11-26
PT90642A (pt) 1989-11-30
AU3769189A (en) 1989-12-12
CN1040033A (zh) 1990-02-28
WO1989011290A1 (en) 1989-11-30
FI905825A7 (fi) 1990-11-26
ATE115146T1 (de) 1994-12-15
DE68919848T2 (de) 1995-05-04
AU626890B2 (en) 1992-08-13
EP0416035A1 (en) 1991-03-13
DK280190A (da) 1990-11-26
IL90356A0 (en) 1989-12-15
EP0416035B1 (en) 1994-12-07
EP0416035A4 (en) 1992-01-15
FI905825A0 (fi) 1990-11-26
BR8907452A (pt) 1991-04-02
ES2012004A6 (es) 1990-02-16
DE68919848D1 (de) 1995-01-19
JPH03504501A (ja) 1991-10-03

Similar Documents

Publication Publication Date Title
Selsted et al. Primary structures of three human neutrophil defensins.
KR900701295A (ko) 양극성 펩타이드류와 그것에 관한 용도
Chen et al. Structural analysis of antioxidative peptides from Soybean. beta.-Conglycinin
Sanger et al. The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates
US4079127A (en) Thymosin alpha 1
Lin et al. Human carbonic anhydrases: XII. The complete primary structure of the C isozyme
KR860004149A (ko) 재조합 dna 기술에 의해 제조된 생리적 활성 물질의 정제방법
Hayashi et al. Amino acid sequence of cytotoxin I from the venom of the Indian cobra (Naja naja)
DE68927379D1 (de) Plättchen blockierende peptide
ES2112255T3 (es) Complejos proteicos que tienen actividad del factor viii:c y su produccion.
KR940005669A (ko) 사이클로펩타이드, 및 점막에 적용시 흡수 촉진제로서의 이의 용도
KR880013977A (ko) 항응고제인 사이클릭 펩타이드
Chiou A novel crystallin from octopus lens
Schenkein et al. Proteases from mouse submaxillary gland
Ohkura et al. Isolation and characterization of a phospholipase A2 inhibitor from the blood plasma of the Thailand cobra Naja naja kaouthia
Milstein Variations in the C-terminal half of immunoglobulin gamma-chains
IE800053L (en) Muraminyl polypeptides
KR890003409A (ko) 점막 투여시 흡수 촉진제로서의 시클릭 펩티드
STRICKLAND et al. The Complete Amino‐Acid Sequence of Histone H2B (2) from Sperm of the Sea Urchin Parechinus angulosus
KR870005014A (ko) 사독(蛇毒) 성장정지 펩티드 및 그 수득 및 정제방법
Kmiecik et al. Primary structure of histone H2A from nucleated erythrocyte of the marine worm Sipunculus nudus presence of two forms of H2A in the sipunculid chromatin
Lee et al. Identification of cardiotoxin with cobramine B, DLF, toxin and cobra venom cytotoxin
DE3751398D1 (de) Substrat-Peptide.
Pootrakul et al. Hemoglobin Siam α215argβ2: A new α-chain variant
Corran et al. The tryptic peptides of rabbit muscle triose phosphate isomerase

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900117

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid